医学
显微镜下多血管炎
流式细胞术
血管炎
肉芽肿伴多发性血管炎
T细胞
受体
外围设备
内分泌学
B细胞
化学
内科学
免疫学
免疫系统
抗体
疾病
作者
Jonathan London,N. Dumoitier,Sébastien Lofek,Jérémie Dion,Benjamin Chaigne,Julie Mocek,Nathalie Thiéblemont,Pascal Cohen,Claire Le Jeunne,Loı̈c Guillevin,Véronique Witko‐Sarsat,Nadine Varin‐Blank,Benjamin Terrier,Luc Mouthon,for the French Vasculitis Study Group (FVSG)
出处
期刊:Rheumatology
[Oxford University Press]
日期:2020-06-26
卷期号:60 (5): 2157-2168
被引量:13
标识
DOI:10.1093/rheumatology/keaa432
摘要
Abstract Objectives To characterize lymphocytes dysregulation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Methods Using flow cytometry, we analysed B- and T-cell subsets in peripheral blood from 37 untreated patients with active disease (29 GPA and 8 MPA) and 22 healthy controls (HCs). Results GPA patients had increased Th2 (1.8 vs 1.0%, P = 0.02), Th9 (1.1 vs 0.2%, P = 0.0007) and Th17 (1.4 vs 0.9%, P = 0.03) cells compared with HC. Patients with MPO-ANCAs had significantly more CD21– B cells than HC or PR3-ANCA patients (6.9 vs 3.3% and 4.4%, P = 0.01). CD69 expressing B cells were significantly higher in GPA and MPA (3.0 and 5.9 vs 1.4%, P = 0.02 and P = 0.03, respectively) compared with HC, whereas B-cell activating factor-receptor expression was decreased in GPA and MPA (median fluorescence intensity ratio 11.8 and 13.7 vs 45.1 in HC, P < 0.0001 and P = 0.003, respectively). Finally, IL-6-producing B cells were increased in GPA vs HC (25.8 vs 14.9%, P < 0.0001) and decreased in MPA vs HC (4.6 vs 14.9%, P = 0.005), whereas TNF-α-producing B cells were lower in both GPA and MPA patients compared with controls (15 and 8.4 vs 30%, P = 0.01 and P = 0.006, respectively). Conclusion Skewed T-cell polarization towards Th2, Th9 and Th17 responses characterizes GPA, whereas B-cell populations are dysregulated in both GPA and MPA with an activated phenotype and a decreased B-cell activating factor-receptor expression. Finally, inflammatory B cells producing IL-6 are dramatically increased in GPA, providing an additional mechanism by which rituximab could be effective.
科研通智能强力驱动
Strongly Powered by AbleSci AI